Carlos Becerra

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad et al. · British Journal of Cancer · 2020 · 850 citations · Full text

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 554 citations

Pharmacological Study, Efficacy Data, Pharmacology +7

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Yu Shi, Weina Gao, Nikki K. Lytle et al. · Nature · 2019 · 413 citations

Tumor Biology, Drug Targeting, Pancreatic Cancer +8

Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Udit Verma, Rama Mohan Surabhi, Aurelia Schmaltieg et al. · PubMed · 2003 · 295 citations

Cancer Biology, Tumor Biology, Oncology +16